Menu
Mineralys Therapeutics, Inc. was formed in 2019. In 2020, Mineralys licensed lorundrostat (MLS-101) from Mitsubishi Tanabe Pharmaceutical Company, who discovered and developed the compound through phase I. Mineralys has subsequently validated lorundrostat’s potential value in hypertension in a phase 2 proof-of-concept study.
Approximately 30% of people trying to manage their hypertension have dysregulated aldosterone1, but their treatment is not targeted to this underlying cause. While aldosterone is not a stable marker, other indicators of enhanced response, such as obesity, may guide treatment with lorundrostat for people with aldosterone-dependent CRMS diseases2.
Jessica Ibbitson is Senior Vice President, Clinical Operations at Mineralys and is responsible for the delivery of our clinical trial strategy and execution. Prior to joining Mineralys, Jessica led the Clinical & General Operations department at ProQR Therapeutics which included Clinical Operations, Project Management and Digital Health Technologies and was the head of Vertex Pharmaceuticals Clinical Site Services department responsible for start-up of cystic fibrosis clinical development programs which led to the expedited approvals of Kalydeco®, Orkambi® and Symdeko®. Jessica has spent her career focusing on diseases with a high unmet medical need and developing new methods for accelerating clinical trials in order to get potential treatments to patients as quickly as possible.
Ms. Karydas currently serves as President and Chief Financial Officer of Flare Therapeutics Inc. where she has been since October 2021. Prior to Flare Therapeutics, she served as the Chief Financial Officer of Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) from July 2020 to October 2021. From April 2017 to May 2020, Ms. Karydas held several roles at Allergan plc, including Senior Vice President of Corporate Strategy and Financial Planning & Analysis. Prior to her senior executive and top manager roles at these biotech and pharmaceutical companies, Ms. Karydas spent more than 15 years in investment banking and asset management roles that focused exclusively on the healthcare space, including biopharmaceuticals, life sciences and medical technologies. Ms. Karydas has previously served on the boards of directors at Elicio Therapeutics, LogicBio Therapeutics, Inc., and Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR). Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Alex Gold, MD has over 20 years of extensive experience in development and commercialization of new therapeutics in the pharmaceutical and biotech industries. His track record includes five products approved and commercialized globally and three companies acquired. He has expertise in operational leadership at the C-suite level, including global clinical development, regulatory approvals, fundraising, corporate strategy, commercialization, academic collaboration and medical affairs.
Dr. Gold is currently Chief Medical Officer at a stealth biotech company in California. He previously served as Chief Medical Officer and President at Sanifit Therapeutics, which was acquired by Vifor Pharma and subsequently CSL, Ltd. Prior to that Dr. Gold was SVP and Head of Clinical Development at Portola Pharmaceuticals, where he built and led the clinical and medical affairs organization, delivering two approved regulatory submissions, AndeXa® and BevyxXa. (Portola was subsequently acquired by Alexion). Prior to Portola Dr. Gold was Head of Clinical Development at Reata Pharmaceuticals after eleven years at AstraZeneca, where his last position was as Executive Director and Development Brand Leader for CRESTOR®, ONGLYZA® and BRILINTA®. In these roles, he led teams and activities related to development, approval and commercialization of these products. During his career, he held multiple leadership positions in various therapeutic areas, including hematology, thrombosis, cardiometabolic, nephrology, inflammation, and oncology.
Dr. Gold is Adjunct Professor at Stanford University School of Medicine and previously was a visiting lecturer at Penn Institute for Translational Medicine and Therapeutics (ITMAT). He has authored numerous publications in peer-reviewed journals, including New England Journal of Medicine, Circulation, and American Heart Journal. He has presented and led symposia on diverse topics related to the science and development of innovative medicines. Dr. Gold received his MD at Harvard Medical School and his BA at Brandeis University. He completed post-graduate medical training at Beth Israel Deaconess Medical Center, Boston in internal medicine, cardiology and clinical research. He also received executive training at Wharton.
Glenn P. Sblendorio was Chief Executive Officer and a member of the board of directors of IVERIC bio, Inc., a publicly-held biotechnology company, from July 2017 until it was acquired by Astellas Pharma in July of 2023. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and was a member of the board of directors of The Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also served as a Managing Director of MPM Capital Advisors from 1998 through 2000. Mr. Sblendorio also serves as a member of the board of directors of Intercept Pharmaceuticals, Inc. and as a member of the board of directors Amicus Therapeutics, Inc. Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program.